Assessment of gene variants in differential response to anti-VEGF agents in AMD
- Research Opportunity
- PhD, Masters by Research, Honours, Master of Biomedical Science
- Project Status
- Surgery, Otolaryngology, Royal Victorian Eye and Ear Hospital
|Prof Paul Baird||Personal web page|
AMD is the leading cause of legal blindness in Australia. A drug treatment for AMD based on the use of anti-vascular endothelial growth factor (VEGF) agents is available for the neovascular (wet) form of disease. However, approximately 10% of individuals do not respond to treatment. Through the use of high-throughput genetic analysis (genome-wide association studies and next-generation sequencing), we have identified a series of potential gene variants that are involved in this differential treatment response. Students will undertake functional assessment of these identified genes using a range of genetic, cellular and protein techniques. The objective of this project is to identify the biological significance of these gene variants in order to identify new targets for drug development.
This project is conducted in Centre for Eye Research Australia, Ocular Genetics Group.
Faculty Research Themes
School Research Themes
PhD, Masters by Research, Honours, Master of Biomedical Science
Graduate Research Students who are interested in joining this project will need to consider their elegibility as well as other Graduate Research requirements before contacting the supervisor of this research
For further information about this research, please contact a supervisor.